Show simple item record

dc.contributor.authorBeksaç, Kemal
dc.contributor.authorAktoz, Fatih
dc.contributor.authorÖrgül, Gökçen
dc.contributor.authorÇelik, Hasan Tolga
dc.contributor.authorÖzgü-Erdinç, A. Seval
dc.contributor.authorBeksaç, M. Sinan
dc.date.accessioned2019-12-12T06:44:11Z
dc.date.available2019-12-12T06:44:11Z
dc.date.issued2018
dc.identifier.issn1309-0399
dc.identifier.urihttps://doi.org/10.4274/jtgga.2017.0057
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994817/
dc.identifier.urihttp://hdl.handle.net/11655/16857
dc.description.abstractObjective: To evaluate “papillary thyroid carcinoma-pregnancy” interaction among cancer survivors. Material and Methods: The clinical records of 8 pregnant women who received treatment for papillary thyroid cancer before their pregnancy were evaluated. Clinical features, pregnancy/perinatal outcomes and high-risk factors were compared with 45 controls who were randomly assigned from the institutional perinatal medicine database. Results: Patients in the cancer group were older than the control group (34.3 vs 29.8 years). The cesarean section rate was higher (62.5% vs 33.3%) and the APGAR scores at the 1st and 5th minutes were lower in the cancer group. Conclusion: Management of pregnancies with papillary thyroid cancer treatment and follow-up requires a multidisciplinary approach with careful antenatal care and perinatal surveillance. Patients who have received papillary thyroid cancer treatment can safely undergo pregnancy.
dc.relation.isversionof10.4274/jtgga.2017.0057
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titlePregnancy In Papillary Thyroid Cancer Survivors
dc.typeinfo:eu-repo/semantics/article
dc.relation.journalJournal of the Turkish German Gynecological Association
dc.contributor.departmentKadın Hastalıkları ve Doğum
dc.identifier.volume19
dc.identifier.issue2
dc.identifier.startpage94
dc.identifier.endpage97
dc.description.indexPubMed


Files in this item

This item appears in the following Collection(s)

Show simple item record